DelveInsight’s “Perivascular epithelioid cell neoplasm – Market Insights, Epidemiology and Market Forecast – 2032“ report delivers an in-depth understanding of the Perivascular Epitheliod Cell Neoplasm, epidemiology insights, Perivascular Epitheliod Cell Neoplasm market trends, therapies and key companies working in the Perivascular Epitheliod Cell Neoplasm Market in the 7MM.
Perivascular Epithelioid Cell Neoplasm Overview
A family of rare tumors that form in the soft tissues of the stomach, intestines, lungs, female reproductive organs, and genitourinary organs. Most Perivascular Epithelioid Cell Neoplasm s are benign (not cancer). They often occur in children with an inherited condition called tuberous sclerosis. Also called a perivascular epithelioid cell tumor.
Perivascular Epithelioid Cell Neoplasm Epidemiology Insights
-
The total number of Perivascular Epithelioid Cell Neoplasm incident cases in the United States was around 250 cases in 2022 and is projected to increase during the forecasted period (2023-2032).
-
The United States contributed to the largest incident population of Perivascular Epithelioid Cell Neoplasm, acquiring ~64% of the 7MM in 2022. Whereas EU4 and the UK, and Japan accounted for around 28% and 8% of the total population share, respectively, in 2022.
-
Among the EU4 countries, Germany accounted for the largest number of Perivascular Epithelioid Cell Neoplasm cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
-
According to DelveInsight estimates, there were around 150 patients in the benign stage and less than 100 patients with malignant Perivascular Epithelioid Cell Neoplasm in the United States in 2022. The incidence is projected to increase during the forecasted period.
-
In 7MM, approximately 70% of the patient share is attributed to females, whereas only 30% of males suffer from Perivascular Epithelioid Cell Neoplasm.
Click here to learn more about the Perivascular Epithelioid Cell Neoplasm Market Landscape
The Report Covers the Perivascular Epithelioid Cell Neoplasm Epidemiology Segmented by:
-
Total Perivascular Epithelioid Cell Neoplasm prevalent cases
-
Total Perivascular Epithelioid Cell Neoplasm type-specific prevalent cases
-
Total Perivascular Epithelioid Cell Neoplasm diagnosed cases
-
Total Perivascular Epithelioid Cell Neoplasm treatable cases
Perivascular Epithelioid Cell Neoplasm Market Outlook
Key Companies Working in the Perivascular Epithelioid Cell Neoplasm Market
-
Aadi Bioscience
-
Sarcoma Oncology Research Center LLC,
-
Novartis Pharmaceuticals
-
CENTOGENE GmbH Rostock
-
Antia Therapeutics AG,
And many others
Perivascular Epithelioid Cell Neoplasm Therapies Covered and Analyzed in the Report
-
Nab-Sirolimus
-
BEZ235
-
Trabectedin
-
Everolimus
-
RAAD001
And many others
Learn more about the Key Companies and Emerging Therapies in the Perivascular Epithelioid Cell Neoplasm Market
Table of Contents
-
Key Insights
-
Perivascular Epithelioid Cell Neoplasm Introduction
-
Executive Summary of Perivascular Epithelioid Cell Neoplasm
-
Disease Background and Overview
-
Epidemiology and patient population
-
Perivascular Epithelioid Cell Neoplasm Emerging Therapies
-
Perivascular Epithelioid Cell Neoplasm Market Outlook
-
Perivascular Epithelioid Cell Neoplasm Market Access and Reimbursement of Therapies
-
Perivascular Epithelioid Cell Neoplasm Market Drivers
-
Perivascular Epithelioid Cell Neoplasm Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Perivascular Epithelioid Cell Neoplasm Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services